← Leaderboards
Valentina Kon
Vanderbilt University Medical Center
$7,107,751
Attributed
$8,584,805
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2008–25$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,584,805 · 6
By mechanism
P01$4,310,306 · 2
R01$4,122,469 · 2
P50$152,030 · 2
Top collaborators
- Annet Kirabo3 shared
- Elaine Shelton3 shared
Most similar at Vanderbilt University Medical Center
Same institution · by research overlap
- Macrae F Linton$20,130,632
- Amy S Major$8,135,070
- Amanda C Doran$3,495,378
- David G Harrison$36,205,139
- Nicole Leanne Ward$14,066,442
Others in their field
Top investigators on “Lipids”
- Constance Ann Benson · University Of California, San Diego$84,289,569
- Alan M Fogelman · University Of California Los Angeles$57,458,120
- Paul M. Ridker · Brigham And Women'S Hospital$56,179,451
- Adrian Hernandez · Duke University$50,769,596
- Garret A Fitzgerald · University Of Pennsylvania$50,340,498
- Richard A Gibbs · Baylor College Of Medicine$49,140,324
Research focus
LipidsKidney DiseasesKidneyIn VivoLinkChronic Kidney FailureFunctional DisorderCardiovascular DiseasesBlood VesselsAccelerationReceptorAffectIn VitroInflammationPathway InteractionsProteinsCellsVascular DiseasesAtherosclerosisCell PhysiologyInflammatoryPathogenesisArterial Fatty StreakMacrophage
Grant awards (21)
Salt Mediated Cross Talk Between Lymphatic Vessels and Immune Cells in Kidney Disease$733,828
R01 · FY2025 · DK · contact PI
Modified Intestinal apoAI-particles and Lymphatics Accelerate CKD-driven CVD$287,931
P01 · FY2025 · HL · contact PI
Salt Mediated Cross Talk Between Lymphatic Vessels and Immune Cells in Kidney Disease$721,712
R01 · FY2024 · DK · contact PI
Modified Intestinal apoAI-particles and Lymphatics Accelerate CKD-driven CVD$389,250
P01 · FY2024 · HL · contact PI
Salt Mediated Cross Talk Between Lymphatic Vessels and Immune Cells in Kidney Disease$760,041
R01 · FY2023 · DK · contact PI
Modified Intestinal apoAI-particles and Lymphatics Accelerate CKD-driven CVD$432,500
P01 · FY2023 · HL · contact PI
Modified Intestinal apoAI-particles and Lymphatics Accelerate CKD-driven CVD$432,500
P01 · FY2022 · HL · contact PI
Modified Intestinal apoAI-particles and Lymphatics Accelerate CKD-driven CVD$432,500
P01 · FY2021 · HL · contact PI
Dysfunctional HDL in Chronic Kidney Disease$471,171
P01 · FY2018 · HL · contact PI
Dysfunctional HDL in Chronic Kidney Disease$471,171
P01 · FY2017 · HL · contact PI
Dysfunctional HDL in Chronic Kidney Disease$471,171
P01 · FY2016 · HL · contact PI
Dysfunctional HDL in Chronic Kidney Disease$461,200
P01 · FY2015 · HL · contact PI
Dysfunctional HDL in Chronic Kidney Disease$460,912
P01 · FY2014 · HL · contact PI
Role of Macrophage-Specific AT1R in Atherosclerosis of Chronic Kidney Dysfunction$379,913
R01 · FY2012 · HL · contact PI
Role of Macrophage-Specific AT1R in Atherosclerosis of Chronic Kidney Dysfunction$383,750
R01 · FY2011 · HL · contact PI
Role of Macrophage-Specific AT1R in Atherosclerosis of Chronic Kidney Dysfunction$383,750
R01 · FY2010 · HL · contact PI
Role of Macrophage-Specific AT1R in Atherosclerosis of Chronic Kidney Dysfunction$383,750
R01 · FY2009 · HL · contact PI
Role of Macrophage-Specific AT1R in Atherosclerosis of Chronic Kidney Dysfunction$375,725
R01 · FY2008 · HL · contact PI
ROLE OF ANGIOTENSIN II IN ATHEROSCLEROSIS$0
P50 · FY2002 · DK
GENETIC VARIANTS IN RENIN ANGIOTENSIN SYSTEM IN PEDIATRIC RENAL DISEASE$0
P50 · FY2001 · DK
GENETIC VARIANTS IN RENIN ANGIOTENSIN SYSTEM IN PEDIATRIC RENAL DISEASE$152,030
P50 · FY2000 · DK